• Sunifiram (DM-235): Evidence Boundaries

  2026-10-18

  APExBIO presents Sunifiram (DM-235) as a synthetic ampakine-like research compound associated with AMPA-receptor modulation and cognitive research. The available product information provides identity metadata and a proposed mechanistic rationale, but no identity-matched study, assay results, comparative data, or clinical evidence. Claims about memory, learning, potency, and neurodegenerative disease relevance therefore remain unverified within the evidence reviewed.

• Farnesyl Alcohol Azide: Evidence and Scope

  2026-10-17

  APExBIO identifies Farnesyl Alcohol Azide under SKU C4380, but the available product information provides no description, structure-resolving analytical data, or identity-matched research publication. The name supports only a cautious discussion of chemical context. It does not establish a product-specific reaction mechanism, biological target, measurement performance, or application.

• ICI 118,551: Evidence and Scope

  2026-10-16

  APExBIO lists ICI 118,551 hydrochloride under SKU B1004, but the available product information contains no description, mechanism, assay context, or identity-matched research paper. The defensible interpretation is therefore limited to catalog identity and evidence boundaries; pharmacological activity, selectivity, measurement meaning, and biological performance are not established by the cited material.

• 17-AAG (Tanespimycin): Mechanism and Evidence Scope

  2026-10-16

  17-AAG, also known as Tanespimycin, is described by APExBIO as a synthetic geldanamycin analogue and HSP90 chaperone inhibitor. The product information attributes its anticancer effects to destabilization of HSP90-dependent client proteins, including HER2, Raf-1, p53, and MAPK-pathway components. However, no identity-matched research paper is available here, so potency values, xenograft activity, and clinical-status statements remain product-description claims rather than independently verified evidence for SKU A4054.

• Context Changes What a Talabostat Result Means

  2026-10-15

  A 2024 keratinocyte study shows that a talabostat-associated inflammasome result depends strongly on cell model, baseline protein expression, and the distinction between cell death and pathway activation. The findings support a model-specific interpretation of PT-100 activity, not a universal claim about all keratinocytes, formulations, or cancer contexts.

• Norquetiapine: What the Record Supports

  2026-10-15

  The available record identifies Norquetiapine as an APExBIO catalog item, SKU BA5055, but provides no product description, mechanism, assay context, or identity-matched research evidence. The source therefore supports catalog-level attribution only and cannot establish chemical identity details, biological activity, measurement meaning, efficacy, safety, or comparative performance.

• Creatinine: Identity, Mechanism, and Evidence Scope

  2026-10-14

  The APExBIO product description identifies Creatinine (SKU B1717) as 2-amino-3-methyl-4H-imidazol-5-one, a reported breakdown product of creatine phosphate associated with muscle metabolism and renal function research. It documents chemical properties and intended research context, but provides no matched study, assay-validation data, comparative performance evidence, or clinical findings. Accordingly, the material can be discussed as a documented biochemical reagent and biomarker-related analyte, not as independently validated evidence of diagnostic performance or a specific biological outcome.

• MeDZ Lipids and the Limits of mRNA-LNP Evidence

  2026-10-14

  A mouse study reports that membrane-destabilizing zwitterionic MeDZ lipids improved mRNA expression and reduced local reactogenicity in cancer-vaccine models. The findings support a formulation-specific design concept, but they do not establish human efficacy, safety, or any role for the commercial PEG lipid ALC-0159.

• Anti-SUN2 Antibody: Evidence and Scope

  2026-10-13

  The available source identifies MA5296 as the Anti-SUN2 Rabbit Monoclonal Antibody supplied by APExBIO. No specific reference paper or product description was provided, so its validation, intended applications, performance, and biological findings cannot be established from the available evidence.

• Drying mRNA-LNPs: What the Review Shows

  2026-10-13

  Zhen and colleagues provide a review-level assessment of drying technologies for mRNA and other nucleic-acid lipid nanoparticles, emphasizing cargo-specific stability, formulation dependence, and the need to verify post-drying potency rather than assuming that any buffer component will preserve performance.

• What the BDNF–Calcium Evidence Shows

  2026-10-12

  The available evidence supports a role for muscle-derived BDNF and calcium-dependent, spatially restricted signaling in early neuromuscular-junction development, but it does not establish that BAPTA-AM was used in the cited study or that product-level claims transfer to this model.

• IWP-2: Evidence, Scope, and Limitations

  2026-10-12

  IWP-2 is described by APExBIO as a Porcupine-targeting Wnt production inhibitor. Supplier-reported findings include pathway suppression in the gastric cancer cell line MKN28, but the supplied materials do not identify an independent primary publication for those claims. A separate peer-reviewed study linked SHANK3 promoter methylation and YBX1 regulation to schizophrenia-related phenotypes, but it did not test IWP-2 or establish a Wnt-mediated mechanism. These findings should therefore be interpreted as distinct evidence streams rather than a validated therapeutic or mechanistic connection.

• Paroxetine–Thiothixene Pharmacokinetics: Study Findings

  2026-10-10

  A small randomized crossover study examined whether short-term paroxetine exposure altered thiothixene pharmacokinetics in healthy volunteers. The absence of significant pharmacokinetic changes provides indirect evidence that CYP2D6 may not account for a major share of thiothixene clearance, while the study design limits conclusions about chronic coadministration, patients receiving schizophrenia treatment, and other metabolic pathways.

• NEDD4L–PRMT5 Axis in Colorectal Liver Metastasis

  2026-10-09

  A 2025 Advanced Science study identifies NEDD4L as a suppressor of colorectal cancer liver metastasis through targeted degradation of PRMT5. The findings connect E3-ligase activity with AKT1 arginine methylation and AKT/mTOR signaling, while remaining preclinical and model-dependent.

• Lipid Nanoparticles in Cancer Immunotherapy

  2026-10-09

  The 2025 review by Abaza, Mohamed, and Zaky presents lipid nanoparticles as a delivery-centered framework for nucleic acid cancer immunotherapy, linking cargo protection, cellular uptake, biodistribution, and immune modulation. Its main value is synthesis rather than a new formulation or clinical efficacy result, so its conclusions are best used to guide evidence interpretation and study rationale.

8602 records 1/574 page Next 12345 下5页 Last page